Obeticholic acid (OCA), a steroidal semisynthetic derivative of chenodeoxycholic acid and a potent FXR agonist, has shown to reduce liver fat and fibrosis in animal models of fatty liver disease, and for this reason it has been extensively studied for the treatment of NASH. This evidence concerns the gene NR1H4 and fatty liver disease.